Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$2.08
-11.1%
$3.20
$2.01
▼
$4.99
$38.26M2.74222,411 shs304,361 shs
Better Choice Company Inc. stock logo
SRXH
Better Choice
$0.80
-22.3%
$1.26
$0.71
▼
$42.61
$16.21M0.881.61 million shs1.08 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.23
-7.9%
$2.02
$0.95
▼
$9.08
$46.41M1.431.48 million shs1.09 million shs
Upexi, Inc. stock logo
UPXI
Upexi
$0.46
-15.7%
$0.92
$0.42
▼
$3.03
$53.93M-0.281.34 million shs2.14 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-11.11%-19.38%-32.90%-34.59%-56.03%
Better Choice Company Inc. stock logo
SRXH
Better Choice
-22.33%-15.95%-27.27%-56.99%-94.93%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-7.87%-31.67%-28.90%-43.84%-50.60%
Upexi, Inc. stock logo
UPXI
Upexi
-15.70%-27.96%-46.89%-57.20%-82.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$2.08
-11.1%
$3.20
$2.01
▼
$4.99
$38.26M2.74222,411 shs304,361 shs
Better Choice Company Inc. stock logo
SRXH
Better Choice
$0.80
-22.3%
$1.26
$0.71
▼
$42.61
$16.21M0.881.61 million shs1.08 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.23
-7.9%
$2.02
$0.95
▼
$9.08
$46.41M1.431.48 million shs1.09 million shs
Upexi, Inc. stock logo
UPXI
Upexi
$0.46
-15.7%
$0.92
$0.42
▼
$3.03
$53.93M-0.281.34 million shs2.14 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-11.11%-19.38%-32.90%-34.59%-56.03%
Better Choice Company Inc. stock logo
SRXH
Better Choice
-22.33%-15.95%-27.27%-56.99%-94.93%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-7.87%-31.67%-28.90%-43.84%-50.60%
Upexi, Inc. stock logo
UPXI
Upexi
-15.70%-27.96%-46.89%-57.20%-82.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.25
Hold$9.83372.36% Upside
Better Choice Company Inc. stock logo
SRXH
Better Choice
0.00
N/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
2.00
Hold$5.00981.78% Upside

Current Analyst Ratings Breakdown

Latest SRXH, THAR, UPXI, and HYPD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Upexi, Inc. stock logo
UPXI
Upexi
Reiterated RatingOverweight$2.00
9/10/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Reiterated RatingOverweight$7.10 ➝ $11.20
9/10/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
UpgradeStrong Sell ➝ Hold
9/10/2026
Upexi, Inc. stock logo
UPXI
Upexi
Boost Price TargetOverweight$1.30 ➝ $2.00
9/8/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Boost Price TargetBuy$7.30 ➝ $8.45
9/4/2026
Upexi, Inc. stock logo
UPXI
Upexi
Reiterated RatingSell (E+)
9/1/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
UpgradeSell (D) ➝ Sell (D+)
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$810K39.78N/AN/A$9.17 per share0.23
Better Choice Company Inc. stock logo
SRXH
Better Choice
-$24.91M-0.65N/AN/A$4.09 per share0.20
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
Upexi, Inc. stock logo
UPXI
Upexi
$25M1.64N/AN/A$0.55 per share0.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$45.31M-$5.35N/A10.40N/A975.68%5.67%5.11%N/A
Better Choice Company Inc. stock logo
SRXH
Better Choice
-$22.77M-$11.74N/AN/AN/A-39.83%-206.10%-60.54%N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A
Upexi, Inc. stock logo
UPXI
Upexi
-$246.07M-$4.14N/AN/AN/A-1,162.51%-157.49%-26.59%2/9/2027 (Estimated)

Latest SRXH, THAR, UPXI, and HYPD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A$1.23N/A$1.23N/A$0.81 million
11/10/2026Q1 2027
Upexi, Inc. stock logo
UPXI
Upexi
-$0.23$0.68+$0.91$0.68$4.20 million$0.43 million
9/17/2026Q4 2026
Upexi, Inc. stock logo
UPXI
Upexi
-$0.11-$0.10+$0.01-$2.3720$5.80 million$6.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
Better Choice Company Inc. stock logo
SRXH
Better Choice
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A
3.76
2.34
Better Choice Company Inc. stock logo
SRXH
Better Choice
N/A
2.38
1.81
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98
Upexi, Inc. stock logo
UPXI
Upexi
0.33
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
Better Choice Company Inc. stock logo
SRXH
Better Choice
12.64%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%
Upexi, Inc. stock logo
UPXI
Upexi
5.68%

Insider Ownership

CompanyInsider Ownership
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
7.50%
Better Choice Company Inc. stock logo
SRXH
Better Choice
33.40%
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
Upexi, Inc. stock logo
UPXI
Upexi
8.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
915.49 million14.33 millionNo Data
Better Choice Company Inc. stock logo
SRXH
Better Choice
4020.27 million1.39 millionNo Data
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable
Upexi, Inc. stock logo
UPXI
Upexi
1088.86 million81.11 millionOptionable

Recent News About These Companies

Upexi (NASDAQ:UPXI) Upgraded to "Hold" at Wall Street Zen
Upexi (UPXI) Stock Rises on Q1 2027 Earnings
Upexi Reports Fiscal First Quarter 2027 Financial Results
Upexi (UPXI) Set to Announce Quarterly Earnings on Wednesday
Upexi (UPXI) Projected to Release Earnings on Wednesday
Upexi Earnings Call: High-Stakes Bet on Solana
Upexi (UPXI) Q4 2026 Earnings Call Transcript
Upexi (UPXI) Stock Falls on Quarterly Earnings
Upexi Amends BitGo Credit Facility

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$2.08 -0.26 (-11.11%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$2.35 +0.27 (+13.17%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Better Choice stock logo

Better Choice NYSE:SRXH

$0.80 -0.23 (-22.33%)
As of 11/20/2026 04:00 PM Eastern

Better Choice Company Inc. operates as a pet health and wellness company. Its products portfolio includes naturally formulated kibble and canned dog and cat foods, freeze-dried raw dog foods and treats, vegan dog foods and treats, oral care products and supplements, as well as toppers, dental products, and chews. The company sells its products under Halo Holistic and Halo Elevate brands. It primarily sells its products through its online portals, as well as through online retailers and pet specialty retailers. The company has operations in the United States, Canada, and select Asian markets, including China. The company was formerly known as Sports Endurance, Inc. and changed its name to Better Choice Company Inc. in March 2019. Better Choice Company Inc. is based in Tampa, Florida.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$1.23 -0.11 (-7.87%)
As of 11/19/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Upexi stock logo

Upexi NASDAQ:UPXI

$0.46 -0.09 (-15.70%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.49 +0.03 (+5.80%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.